Semax 30mg· 30mg

The molecular mechanism of semax has been investigated in multiple model systems. The peptide does not directly activate the canonical melanocortin receptors with high affinity, distinguishing its pharmacology from that of the parent ACTH or alpha-MSH. Instead, observed effects appear to be mediated through upregulation of BDNF and NGF expression in hippocampus, cortex, and other brain regions, with downstream activation of TrkB receptor signaling and CREB-dependent transcription.

Additional reported mechanisms include modulation of monoaminergic neurotransmission, with effects on dopamine and serotonin systems documented in microdialysis studies. The peptide has also been reported to influence the kallikrein-kinin system and to modulate inflammatory cytokine networks in brain tissue. The Pro-Gly-Pro C-terminal extension stabilizes the molecule against aminopeptidase cleavage and supports the intranasal administration route used in much of the research literature.